- Home
- MYGN vs HZO Comparison
MYGN vs HZO Comparison
Compare MYGN & HZO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- HZO
- Stock Information
- Founded
- MYGN 1991
- HZO 1998
- Country
- MYGN United States
- HZO United States
- Employees
- MYGN N/A
- HZO N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- HZO Auto & Home Supply Stores
- Sector
- MYGN Health Care
- HZO Consumer Discretionary
- Exchange
- MYGN Nasdaq
- HZO Nasdaq
- Market Cap
- MYGN 423.1M
- HZO 499.9M
- IPO Year
- MYGN 1995
- HZO 1998
- Fundamental
- Price
- MYGN $6.02
- HZO $28.13
- Analyst Decision
- MYGN Hold
- HZO Strong Buy
- Analyst Count
- MYGN 13
- HZO 4
- Target Price
- MYGN $13.50
- HZO $33.25
- AVG Volume (30 Days)
- MYGN 2.4M
- HZO 343.1K
- Earning Date
- MYGN 08-05-2025
- HZO 07-24-2025
- Dividend Yield
- MYGN N/A
- HZO N/A
- EPS Growth
- MYGN N/A
- HZO N/A
- EPS
- MYGN N/A
- HZO N/A
- Revenue
- MYGN $832,900,000.00
- HZO $2,320,257,000.00
- Revenue This Year
- MYGN N/A
- HZO N/A
- Revenue Next Year
- MYGN $6.64
- HZO $3.41
- P/E Ratio
- MYGN N/A
- HZO N/A
- Revenue Growth
- MYGN 3.83
- HZO N/A
- 52 Week Low
- MYGN $3.76
- HZO $16.85
- 52 Week High
- MYGN $29.30
- HZO $37.86
- Technical
- Relative Strength Index (RSI)
- MYGN 62.34
- HZO 66.93
- Support Level
- MYGN $5.23
- HZO $24.87
- Resistance Level
- MYGN $6.07
- HZO $26.52
- Average True Range (ATR)
- MYGN 0.39
- HZO 1.13
- MACD
- MYGN 0.05
- HZO 0.42
- Stochastic Oscillator
- MYGN 81.27
- HZO 96.33
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About HZO MarineMax Inc. (FL)
MarineMax Inc is a United-States-based company that sells new and used recreational boats under premium brands, and related marine products, like engines, parts, and accessories. The company is also engaged in other businesses, including providing services of repair, maintenance, and storage; managing related boat financing, insurance, and others; offering brokerage sales of boats and yachts; and operating a yacht charter business. The reportable segments of the company are Retail Operations and Product Manufacturing. The Retail Operations segment generates the majority of the company's revenue. The sale of new and used boats accounts for the majority of the company's total revenue. It serves customers across the U.S.